GlassScriptPhysician profile
Joel Mccloud
NPI 1801836457
$26,578.68
in general payments reported to CMS, 2019-2025
51 companies · $1,778 in 2025
The $1,778 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,265 · 2020: $4,588 · 2021: $1,966 · 2022: $2,036 · 2023: $2,994 · 2024: $3,951 · 2025: $1,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,757 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,825 · Travel and Lodging: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,757.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,825.00 |
| Travel and Lodging | $140.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $9,411.86 | 2019-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $2,808.48 | 2022-2025 | Amvuttra |
| Novo Nordisk INC | $1,974.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,517.28 | 2019-2025 | Breztri, Wainua, Farxiga |
| Pfizer INC. | $1,260.04 | 2019-2025 | |
| Lilly USA, LLC | $886.53 | 2019-2025 | Mounjaro, Jardiance |
| Dexcom, INC. | $854.92 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Sanofi-Aventis U.S. LLC | $812.51 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $677.46 | 2021-2025 | |
| Arbor Pharmaceuticals, INC. | $662.58 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $650.41 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $639.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $475.04 | 2019-2021 | |
| Abbott Laboratories | $380.62 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $293.11 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Mccloud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.